Literature DB >> 1506857

Production of soluble autocrine inhibitory factors by human glioma cell lines.

W T Couldwell1, V W Yong, P Dore-Duffy, M S Freedman, J P Antel.   

Abstract

Gliomas in vitro exhibit density-limited growth upon the attainment of confluency, an effect usually attributed to cell-cell contact inhibition. Since gliomas have been demonstrated to secrete an array of soluble factors which can enhance tumor growth, we undertook this study to ascertain whether production of soluble factors by the tumor may also inhibit growth in an autocrine manner, and whether production of such factors is associated with the growth phase of the glioma. We observed that cell-conditioned medium (supernatants) from non-confluent glioma cultures induced growth, while confluent culture supernatants produced pronounced growth suppression. These latter supernatants enhanced proliferation of non-transformed astrocytes. Supernatants derived from all stages of confluency produced inhibition of lymphocyte proliferation. To characterize these factors, dialyzed supernatant was tested and found to continue to produce lymphocyte suppression but no glioma growth limitation. Growth of tumors in indomethacin or in acetylsalicylic acid to abolish prostanoid synthesis abrogated the inhibitory influence on glioma growth but only partially reversed the lymphocyte suppressive capacity. These studies suggest that gliomas do produce a growth phase dependent autocrine inhibitory factor(s), and that the production of these small molecular weight factors is at least partially under control of the cyclooxygenase pathway.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1506857     DOI: 10.1016/0022-510x(92)90026-h

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  5 in total

Review 1.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

Review 2.  Engineering strategies to mimic the glioblastoma microenvironment.

Authors:  Andrew Rape; Badriprasad Ananthanarayanan; Sanjay Kumar
Journal:  Adv Drug Deliv Rev       Date:  2014-08-29       Impact factor: 15.470

Review 3.  Remodeling the blood-brain barrier microenvironment by natural products for brain tumor therapy.

Authors:  Xiao Zhao; Rujing Chen; Mei Liu; Jianfang Feng; Jun Chen; Kaili Hu
Journal:  Acta Pharm Sin B       Date:  2017-09-01       Impact factor: 11.413

4.  Reduced expression of a gene proliferation signature is associated with enhanced malignancy in colon cancer.

Authors:  A Anjomshoaa; Y-H Lin; M A Black; J L McCall; B Humar; S Song; R Fukuzawa; H-S Yoon; B Holzmann; J Friederichs; A van Rij; M Thompson-Fawcett; A E Reeve
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640

Review 5.  Dendritic cell vaccines for high-grade gliomas.

Authors:  Matthew E Eagles; Farshad Nassiri; Jetan H Badhiwala; Suganth Suppiah; Saleh A Almenawer; Gelareh Zadeh; Kenneth D Aldape
Journal:  Ther Clin Risk Manag       Date:  2018-07-26       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.